medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 6

<< Back Next >>

Rev Mex Urol 2020; 80 (6)

Prostate cancer in Mexico: epidemiologic experience at the Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”

Rubí-López B, Real-Cárabes JJ, Magaña-Gutiérrez A, Ibarra-Navarro EI, Andrade-Pérez FJ, Sánchez-Mejía P, Alfaro-Alcocer JA

Language: Spanish
References: 17
Page: 1-8
PDF size: 170.59 Kb.


ABSTRACT

Aim: To know the epidemiology, treatment, and follow-up of patients with prostate cancer at the Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”.
Materials and methods: A retrospective, descriptive, observational study was conducted on 196 patients with prostate cancer that were seen within the time frame of 2015 and 2020 at the Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”.
Results: Of the 196 cases analyzed, mean age at disease presentation was 72.02 years (±8.77), 53.5% did not have a primary school educational level, and 87.7% had no formal employment. Mean body mass index was 25.43 kg/m2 (±3.13) and the most frequent risk factors were smoking, high blood pressure, and diabetes mellitus. Mean prostate-specific antigen level before treatment was 17.59 ng/ml. Of the cases treated, 31.07% underwent surgery, 55.05% received hormone therapy, and 1.02% were under surveillance. Only 12 cases (6.12%) of death were associated with prostate cancer and 37.75% of the study population was lost to follow-up.
Study limitations: Sample size, single-center study.
Value: Ours is a recent epidemiologic study on prostate cancer in Guadalajara, Jalisco.
Conclusions: There was a high degree of sociocultural marginalization in the population with prostate cancer analyzed, as well as associated risk factors that limited the indication for treatments with curative intent. Said factors negatively impacted adequate patient follow-up.


REFERENCES

  1. Saxby H, Mikropoulos C, Boussios S. An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer. Diagnostics (Basel). 2020 Jul 31;10(8). doi: https://doi.org/10.3390/diagnostics10080549

  2. National Comprehensive Cancer Network. Prostate cancer. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 May;2(3):224–48. doi: https://doi. org/10.6004/jnccn.2004.0021

  3. Aldaco-Sarvide F, Pérez-Pérez P, Cervantes- Sánchez G, Torrecillas-Torres L, Erazo-Valle- Solís AA, Cabrera-Galeana P, et al. Mortalidad por Cáncer en México: actualización 2015. GAMO. 2019 Apr 9;17(1):579. doi: 10.24875/j. gamo.M18000105

  4. Torres-Sánchez LE, Espinoza-Giacinto R, Rojas- Martínez R, Escamilla-Nuñez C, Vázquez- Salas RA, Campuzano JC, et al. Prostate cancer mortality according to marginalization status in Mexican states from 1980 to 2013. Salud pública Méx. 2016 Apr;58:179–86. doi: https://doi. org/10.21149/spm.v58i2.7787

  5. Lajous M, Cooperberg MR, Rider J, Manzanilla-García HA, Gabilondo-Navarro FB, Rodríguez-Covarrubias FT, et al. Prostate cancer screening in low- and middle-income countries: the Mexican case. Salud Publica Mex. 2019 Aug;61(4):542–4. doi: https://doi. org/10.21149/10373

  6. Scavuzzo A, Noveron NR, Rios ZS, Rios MJ. P088 Prostate cancer in area without screening. European Urology Supplements. 2014;13(5):142–3.

  7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394– 424. doi: https://doi.org/10.3322/caac.21492

  8. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63–89. doi: https://doi.org/10.14740/wjon1191

  9. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):604–9.

  10. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011 Jun 22;305(24):2548–55. doi: https://doi. org/10.1001/jama.2011.879

  11. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate. 2005 Mar 1;62(4):316–21. doi: https://doi.org/10.1002/ pros.20121

  12. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012 Feb 16;12(3):159–69. doi: https://doi.org/10.1038/nrc3215

  13. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, et al. Followup of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 13;377(2):132–42. doi: https://doi. org/10.1056/nejmoa1615869

  14. Bratu O, Oprea I, Marcu D, Spinu D, Niculae A, Geavlete B, et al. Erectile dysfunction post-radical prostatectomy - a challenge for both patient and physician. J Med Life. 2017 Mar;10(1):13–8.

  15. Moncada I, López I, Ascencios J, Krishnappa P, Subirá D. Complications of robot assisted radical prostatectomy. Arch Esp Urol. 2019;72(3):266– 76.

  16. Muñoz MN, Sossa LA, Grisales A, Rodríguez JD. Creencias sobre el cáncer de próstata en población masculina mayor de 45 años. Santa rosa de cabal, 2010. Cultura del cuidado. 2011;8:62–62.

  17. Guillén IR, Solís FJÁ. Percepciones de población masculina respecto al cáncer de próstata: un aporte a la salud pública.




2020     |     www.medigraphic.com